Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

(2023) Paula Rodriguez-Otero et al.   NEW ENGLAND JOURNAL OF MEDICINE

CARTITUDE-1 final results: Phase 1b/2 study of ciltacabtagene autoleucel in heavily pretreated patients with relapsed/refractory multiple myeloma.

(2023) Yi Lin et al.   JOURNAL OF CLINICAL ONCOLOGY

VP5-2022: Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized phase III trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)

(2022) P. Moreau et al.   ANNALS OF ONCOLOGY

Incidence and management of CAR-T neurotoxicity in patients with multiple myeloma treated with ciltacabtagene autoleucel in CARTITUDE studies

(2022) Adam D. Cohen et al.   Blood Cancer Journal

Ciltacabtagene Autoleucel, an Anti–B-cell Maturation Antigen Chimeric Antigen Receptor T-Cell Therapy, for Relapsed/Refractory Multiple Myeloma: CARTITUDE-1 2-Year Follow-Up

(2022) Thomas Martin et al.   JOURNAL OF CLINICAL ONCOLOGY

P-240: Real-world assessment of treatment patterns and outcomes in patients with lenalidomide-refractory relapsed multiple myeloma from the SEER-Medicare database

(2022) Binod Dhakal et al.   Clinical Lymphoma Myeloma & Leukemia

Ciltacabtagene Autoleucel (Cilta-cel), a BCMA-Directed CAR-T Cell Therapy, in Patients with Multiple Myeloma (MM) and Early Relapse after Initial Therapy: CARTITUDE-2 Cohort B 18-Month Follow-up

(2022) Niels WCJ Van De Donk et al.   BLOOD

How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma

(2022) Felipe de Arriba de la Fuente et al.   Cancers

Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial

(2021) Philippe Moreau et al.   LANCET

Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b/2 open-label study

(2021) Jesus G Berdeja et al.   LANCET

Daratumumab plus pomalidomide and dexamethasone versus pomalidomide and dexamethasone alone in previously treated multiple myeloma (APOLLO): an open-label, randomised, phase 3 trial

(2021) Meletios A Dimopoulos et al.   LANCET ONCOLOGY

Real‐world data on survival improvement in patients with multiple myeloma treated at a single institution over a 45‐year period

(2021) Luis Gerardo Rodríguez‐Lobato et al.   BRITISH JOURNAL OF HAEMATOLOGY

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): updated outcomes from a randomised, multicentre, open-label, phase 3 study

(2021) Saad Z Usmani et al.   LANCET ONCOLOGY

Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 study

(2020) Meletios Dimopoulos et al.   LANCET

Sequencing multiple myeloma therapies with and after antibody therapies

(2020) Niels W. C. J. van de Donk   Hematology-American Society of Hematology Education Program

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

(2019) Paul G Richardson et al.   LANCET ONCOLOGY

ASBMT Consensus Grading for Cytokine Release Syndrome and Neurological Toxicity Associated with Immune Effector Cells

(2018) Daniel W Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Interpreting clinical trial data in multiple myeloma: translating findings to the real-world setting

(2018) Paul G. Richardson et al.   Blood Cancer Journal

Multiple myeloma: patient outcomes in real-world practice

(2016) Kwee Yong et al.   BRITISH JOURNAL OF HAEMATOLOGY

Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma

(2016) Antonio Palumbo et al.   NEW ENGLAND JOURNAL OF MEDICINE

Designing therapeutic cancer vaccine trials with delayed treatment effect

(2016) Zhenzhen Xu et al.   STATISTICS IN MEDICINE

Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1

(2011) S. V. Rajkumar et al.   BLOOD